81 related articles for article (PubMed ID: 21418965)
1. [Comparison of MGMT and ERCC₂ expression in temozolomide for the treatment of malignant glioma drug resistance and their genetic relationship].
Hou X; Zhao Y; Zheng YR; Wang JJ; Wu ZC; Sun JH
Zhonghua Yi Xue Za Zhi; 2011 Jan; 91(1):56-8. PubMed ID: 21418965
[TBL] [Abstract][Full Text] [Related]
2. Correlations of MGMT genetic polymorphisms with temozolomide resistance and prognosis of patients with malignant gliomas: a population-based study in China.
Wang HW; Xu ZK; Song Y; Liu YG
Cancer Gene Ther; 2017 May; 24(5):215-220. PubMed ID: 28409559
[TBL] [Abstract][Full Text] [Related]
3. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.
Paz MF; Yaya-Tur R; Rojas-Marcos I; Reynes G; Pollan M; Aguirre-Cruz L; García-Lopez JL; Piquer J; Safont MJ; Balaña C; Sanchez-Cespedes M; García-Villanueva M; Arribas L; Esteller M
Clin Cancer Res; 2004 Aug; 10(15):4933-8. PubMed ID: 15297393
[TBL] [Abstract][Full Text] [Related]
4. Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?
Tanaka S; Akimoto J; Narita Y; Oka H; Tashiro T
J Neurosurg; 2014 Oct; 121(4):818-26. PubMed ID: 25105699
[TBL] [Abstract][Full Text] [Related]
5. [Individualized chemotherapy based on drug sensitivity and resistance assay and MGMT protein expression for patients with malignant glioma--analysis of 42 cases].
Zhang JP; Shi HL; Sai K; Yue WY; Mu YG; Zhang XH; Chen ZP
Ai Zheng; 2006 Dec; 25(12):1533-7. PubMed ID: 17166381
[TBL] [Abstract][Full Text] [Related]
6. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
Jha P; Suri V; Jain A; Sharma MC; Pathak P; Jha P; Srivastava A; Suri A; Gupta D; Chosdol K; Chattopadhyay P; Sarkar C
Neurosurgery; 2010 Dec; 67(6):1681-91. PubMed ID: 21107199
[TBL] [Abstract][Full Text] [Related]
7. Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter.
Alonso MM; Gomez-Manzano C; Bekele BN; Yung WK; Fueyo J
Cancer Res; 2007 Dec; 67(24):11499-504. PubMed ID: 18089777
[TBL] [Abstract][Full Text] [Related]
8. Molecular characteristics of pediatric non-ependymal, non‑pilocytic gliomas associated with resistance to temozolomide.
Ezaki T; Sasaki H; Hirose Y; Miwa T; Yoshida K; Kawase T
Mol Med Rep; 2011; 4(6):1101-5. PubMed ID: 21874248
[TBL] [Abstract][Full Text] [Related]
9. [Detection of O6-methylguanine-DNA methyltransferase promoter methylation in chemotherapy for glioma].
Zheng CQ; Ji SP; Gong F; Li AM; Tai JL; Zhang YP
Ai Zheng; 2009 Jun; 28(6):575-80. PubMed ID: 19635193
[TBL] [Abstract][Full Text] [Related]
10. Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications.
Zhang J; Stevens MF; Laughton CA; Madhusudan S; Bradshaw TD
Oncology; 2010; 78(2):103-14. PubMed ID: 20357518
[TBL] [Abstract][Full Text] [Related]
11. New (alternative) temozolomide regimens for the treatment of glioma.
Wick W; Platten M; Weller M
Neuro Oncol; 2009 Feb; 11(1):69-79. PubMed ID: 18772354
[TBL] [Abstract][Full Text] [Related]
12. Chemoresistance to temozolomide in human glioma cell line U251 is associated with increased activity of O6-methylguanine-DNA methyltransferase and can be overcome by metronomic temozolomide regimen.
Pan Q; Yang XJ; Wang HM; Dong XT; Wang W; Li Y; Li JM
Cell Biochem Biophys; 2012 Jan; 62(1):185-91. PubMed ID: 21892781
[TBL] [Abstract][Full Text] [Related]
13. The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity.
Remington M; Chtchetinin J; Ancheta K; Nghiemphu PL; Cloughesy T; Lai A
Neuro Oncol; 2009 Feb; 11(1):22-32. PubMed ID: 18812520
[TBL] [Abstract][Full Text] [Related]
14. Preliminary individual adjuvant therapy for gliomas based on the results of molecular biological analyses for drug-resistance genes.
Tanaka S; Kamitani H; Amin MR; Watanabe T; Oka H; Fujii K; Nagashima T; Hori T
J Neurooncol; 2000; 46(2):157-71. PubMed ID: 10894369
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas.
Brell M; Tortosa A; Verger E; Gil JM; Viñolas N; Villá S; Acebes JJ; Caral L; Pujol T; Ferrer I; Ribalta T; Graus F
Clin Cancer Res; 2005 Jul; 11(14):5167-74. PubMed ID: 16033832
[TBL] [Abstract][Full Text] [Related]
16. Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.
Nguyen SA; Stechishin OD; Luchman HA; Lun XQ; Senger DL; Robbins SM; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Sep; 20(18):4894-903. PubMed ID: 25078279
[TBL] [Abstract][Full Text] [Related]
17. Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT.
Fukushima T; Takeshima H; Kataoka H
Anticancer Res; 2009 Nov; 29(11):4845-54. PubMed ID: 20032445
[TBL] [Abstract][Full Text] [Related]
18. Individual adjuvant therapy for malignant gliomas based on O6-methylguanine-DNA methyltransferase messenger RNA quantitation by real-time reverse-transcription polymerase chain-reaction.
Tanaka S; Akimoto J; Kobayashi I; Oka H; Ujiie H
Oncol Rep; 2008 Jul; 20(1):165-71. PubMed ID: 18575733
[TBL] [Abstract][Full Text] [Related]
19. Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.
Pyko IV; Nakada M; Sabit H; Teng L; Furuyama N; Hayashi Y; Kawakami K; Minamoto T; Fedulau AS; Hamada J
Carcinogenesis; 2013 Oct; 34(10):2206-17. PubMed ID: 23715499
[TBL] [Abstract][Full Text] [Related]
20. A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy.
Jiang G; Wei ZP; Pei DS; Xin Y; Liu YQ; Zheng JN
Biochem Biophys Res Commun; 2011 Mar; 406(3):311-4. PubMed ID: 21329652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]